Merck submits modified niacin to FDA

Share this article:
Merck's Cordaptive, an extended-release niacin combined with a flushing inhibitor, has been filed for approval with the FDA, the firm said.

Cordaptive could represent Merck's latest entrée into the $18-billion market for cholesterol drugs. Its statin Zocor (simvastatin) went off patent last year, but another cholesterol-lowering drug Vytorin, which Merck co-markets with Schering-Plough, has sold well.

Drugs that raise HDL, or “good,” cholesterol are considered a new direction for treatment. Flushing is the only known side effect of niacin, and analysts believe a more tolerable form could be a significant advance.

Back in March, Lehman Bros. analyst Tony Butler told MM&M that Cordaptive, then known as MK-524A, could earn between $800 million and $1 billion “or substantially more, if the clinical outcomes suggests a mortality benefit.”

Merck expects to present Phase III data at next month's European Society of Cardiology meeting and in November at a gathering of the American Heart Association.

The drug is designed to be used alone or in combination with a statin. MK-524B, Merck's combination of Cordaptive plus simvastatin (Zocor), is in Phase III trials.

An FDA decision for Cordaptive is anticipated in the second quarter of 2008, Merck said in a statement yesterday. It also plans to file for approval outside the US.

Niaspan, a branded, extended-release form of niacin sold by Kos, had US sales of $473.8 million last year, a 24% increase over 2005. Kos was bought by Abbott Labs in 2006.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.